US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sinovac Biotech

6.47

0.0000

Volume:- -

Turnover:- -

Market Cap:642.44M

PE:6.66

High:6.47

Open:6.47

Low:6.47

Close:6.47

Loading ...

Overview Company News Filings

Heng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholders

BRIEF-Heng Ren Partners Says Sinovac Should Distribute $8.9 Bln In Cash To Shareholders

Heng Ren Partners in Letter Says Sinovac Should Distribute $8.9 Bln in Cash to Shareholders

THOMSON REUTERS

Press Release: Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

Saif Partners Iv Lp-Requisition for Purposes of Electing of Simon Anderson, Shan Fu, Shuge Jiao, Chiang Li, Yuk Lam Lo, Yumin Qiu to Sinovac's Board

THOMSON REUTERS

Saif Partners Iv Lp- Requisition for Purposes of Removing Each of David Guowei Wang, PengFei Li, and Jianzeng Cao From Sinovac Biotech's Board

THOMSON REUTERS

Sinovac Biotech Ltd: New Board Is Working to Respond to Nasdaq's Questions and Requests so as to Provide for Continued Listing of Shares

THOMSON REUTERS

Sinovac Announces New Board Pursuant to Privy Council Judgment and Order

THOMSON REUTERS

Sinovac Biotech Ltd: New Board Has Initiated Process to Cancel Invalid Exchange Shares

THOMSON REUTERS

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

BRIEF-Sinovac Issues Statement Regarding Privy Council Judgment

Sinovac Biotech: Privy Council Ruled Co's Rights Agreement Is Invalid

THOMSON REUTERS

Sinovac: Privy Council in London Rules 2018 Sinovac Board Election Valid

THOMSON REUTERS

Sinovac Issues Statement Regarding Privy Council Judgment

THOMSON REUTERS

SINOVAC Issues Statement Regarding Privy Council Judgment

Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD

MT Newswires Live

Sinovac Biotech initiates clinical trial on a HFMD vaccine candidate

Sinovac Initiated a Phase Iii Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (Hfmd)

THOMSON REUTERS

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SVA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","market":"US","secType":"STK","nameCN":"Sinovac Biotech","latestPrice":6.47,"timestamp":1749494023673,"preClose":6.47,"halted":3,"volume":0,"delay":0,"floatShares":59508401,"shares":99294743,"eps":0.971025,"marketStatus":"Halted","change":0,"latestTime":"06-09 14:33:43 EDT","open":6.47,"high":6.47,"low":6.47,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.971025,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749499200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1102482000000,"exchange":"NASDAQ","adjPreClose":6.47,"dividendRate":8.500773,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","floatShares":59508401,"roa":"11.46%","roe":"25.15%","lyrEps":1.055174,"shares":99294743,"dividePrice":55,"high":6.47,"amplitude":0,"preClose":6.47,"low":6.47,"week52Low":6.47,"pbRate":"0.86","week52High":6.47,"institutionHeld":0.0546,"latestPrice":6.47,"eps":0.971025,"divideRate":8.500773,"volume":0,"delay":0,"ttmEps":0.971025,"open":6.47,"prevYearClose":6.47,"prevWeekClose":6.47,"prevMonthClose":6.47,"prevQuarterClose":6.47,"fiveDayClose":6.47,"twentyDayClose":6.47,"sixtyDayClose":6.47},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521231764","title":"Heng Ren ‘demands’ Sinovac Biotech distribute $8.9B in cash to shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2521231764","media":"TipRanks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521231764?lang=en_us&edition=fundamental","pubTime":"2025-03-21 23:15","pubTimestamp":1742570108,"startTime":"0","endTime":"0","summary":"Sinovac Biotech  shareholder Heng Ren Partners, LLC funds sent an open letter to Sinovac’s shareholders outlining the significant and decisive action that Sinovac’s Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac’s Board of Directors announce a distribution of $8.9B in cash to its shareholders and cause the resumption of trading of the company’s shares. “After announcing a plan to distribute cash to shareholders, the Company must take all action necessary to cause the resumption of trading of Sinovac’s shares on NASDAQ. The Board must immediately take and disclose all steps that it is taking to make this happen. The Board must inform shareholders of a clear timeline as to when the trading of Sinovac’s shares will resume on NASDAQ. The Board must prevent any trading, by Company management or otherwise, of Sinovac’s shares until full disclosure is made of the Company’s financial condition and other material in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/heng-ren-demands-sinovac-biotech-151508853.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heng-ren-demands-sinovac-biotech-151508853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2521498813","title":"BRIEF-Heng Ren Partners Says Sinovac Should Distribute $8.9 Bln In Cash To Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2521498813","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521498813?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:39","pubTimestamp":1742495981,"startTime":"0","endTime":"0","summary":"BRIEF-Heng Ren Partners Says Sinovac Should Distribute $8.9 Bln In Cash To ShareholdersMarch 20 (Reuters) - Heng Ren Partners:SINOVAC MUST TAKE ACTIONS TO DISTRIBUTE CASH TO SHAREHOLDERSIN LETTER SAYS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q314E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2520630304","title":"Heng Ren Partners in Letter Says Sinovac Should Distribute $8.9 Bln in Cash to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2520630304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520630304?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:09","pubTimestamp":1742483386,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q314E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2520463255","title":"Press Release: Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2520463255","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520463255?lang=en_us&edition=fundamental","pubTime":"2025-03-20 23:05","pubTimestamp":1742483100,"startTime":"0","endTime":"0","summary":"Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading. BOSTON, March 20, 2025 /CNW/ -- Sinovac Biotech Ltd.   shareholder Heng Ren Partners, LLC funds  today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares.Heng Ren calls for Sinovac's Board to take decisive and immediate action.  S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","MNQmain","SVA","USAW.SI","SQQQ","PSQ","BK4139","TSYW.SI","NVIW.SI","NQmain","USJW.SI","QID",".IXIC","TQQQ"],"gpt_icon":1},{"id":"2520902212","title":"Saif Partners Iv Lp-Requisition for Purposes of Electing of Simon Anderson, Shan Fu, Shuge Jiao, Chiang Li, Yuk Lam Lo, Yumin Qiu to Sinovac's Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2520902212","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520902212?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:26","pubTimestamp":1742383616,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20I4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2520690264","title":"Saif Partners Iv Lp- Requisition for Purposes of Removing Each of David Guowei Wang, PengFei Li, and Jianzeng Cao From Sinovac Biotech's Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2520690264","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520690264?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:26","pubTimestamp":1742383616,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20I4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2514561323","title":"Sinovac Biotech Ltd:  New Board Is Working to Respond to Nasdaq's Questions and Requests so as to Provide for Continued Listing of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2514561323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514561323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA6TBBYR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2514323306","title":"Sinovac Announces New Board Pursuant to Privy Council Judgment and Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2514323306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514323306?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA6TBBYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2514235603","title":"Sinovac Biotech Ltd: New Board Has Initiated Process to Cancel Invalid Exchange Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2514235603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514235603?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA6TBBYR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2514997323","title":"SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2514997323","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514997323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"BEIJING, February 28, 2025----Sinovac Biotech Ltd.  , a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order  from the Privy Council following the previously announced Privy Council Judgment  which ruled, among others, that  the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and  the Company’s Rights Agreement  was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order.As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement , including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled.SINOVAC’s New Board is committed to acting in the best interests of the Company as well as maximizing the value ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sinovac-announces-board-pursuant-privy-120000247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2503991326","title":"BRIEF-Sinovac Issues Statement Regarding Privy Council Judgment","url":"https://stock-news.laohu8.com/highlight/detail?id=2503991326","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503991326?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:16","pubTimestamp":1737033408,"startTime":"0","endTime":"0","summary":"BRIEF-Sinovac Issues Statement Regarding Privy Council JudgmentJan 16 (Reuters) - Sinovac Biotech Ltd SVA.O:SINOVAC ISSUES STATEMENT REGARDING PRIVY COUNCIL JUDGMENTSINOVAC: PRIVY COUNCIL IN LONDON RU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC0IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2503999978","title":"Sinovac Biotech: Privy Council Ruled Co's Rights Agreement Is Invalid","url":"https://stock-news.laohu8.com/highlight/detail?id=2503999978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503999978?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:01","pubTimestamp":1737032465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC0IR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2503999922","title":"Sinovac: Privy Council in London Rules 2018 Sinovac Board Election Valid","url":"https://stock-news.laohu8.com/highlight/detail?id=2503999922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503999922?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:01","pubTimestamp":1737032465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC0IR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2503999839","title":"Sinovac Issues Statement Regarding Privy Council Judgment","url":"https://stock-news.laohu8.com/highlight/detail?id=2503999839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503999839?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:01","pubTimestamp":1737032465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nFWN3OC0IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2503299418","title":"SINOVAC Issues Statement Regarding Privy Council Judgment","url":"https://stock-news.laohu8.com/highlight/detail?id=2503299418","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503299418?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:01","pubTimestamp":1737032460,"startTime":"0","endTime":"0","summary":"BEIJING, January 16, 2025----Sinovac Biotech Ltd.  , a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company’s Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week.SINOVAC’s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC’s significant value for the benefit of all shareholders.Since the 2018 Annual General Meeting, the Company has a strong track-record of creating tremendous value for all shareholders, having implemented several innovative, life-saving, and value-creating initiatives, including SINOVAC’s leading role in combating the global COVID-19 pandemic delivering 2.9 bil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sinovac-issues-statement-regarding-privy-130100009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4585","SVA","BK4139","BNTX","BK4551","BK4535","BK4588","BK4568"],"gpt_icon":0},{"id":"2491469482","title":"Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2491469482","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491469482?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:21","pubTimestamp":1734358872,"startTime":"0","endTime":"0","summary":"Sinovac Biotech  said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16.The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children aged 6 to 71 months.Sinovac said it is also developing a tetravalent vaccine targeting four major enteroviruses, which was recently approved for clinical trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVA.AU","SSI","BK4139","SVA"],"gpt_icon":0},{"id":"2491666580","title":"Sinovac Biotech initiates clinical trial on a HFMD vaccine candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2491666580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491666580?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:35","pubTimestamp":1734345320,"startTime":"0","endTime":"0","summary":"Sinovac Biotech (SVA) kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sinovac-biotech-initiates-clinical-trial-on-a-hfmd-vaccine-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sinovac-biotech-initiates-clinical-trial-on-a-hfmd-vaccine-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2491940668","title":"Sinovac Initiated a Phase Iii Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (Hfmd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491940668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491940668?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:04","pubTimestamp":1734343440,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUABR43J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2491739668","title":"SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491739668","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491739668?lang=en_us&edition=fundamental","pubTime":"2024-12-16 18:04","pubTimestamp":1734343440,"startTime":"0","endTime":"0","summary":"The first phase III clinical trial on a multivalent HFMD vaccine in the world. BEIJING, December 16, 2024----Sinovac Biotech Ltd.  , a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71  and Coxsackievirus 16 . Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide.SINOVAC has initiated a phase I/II clinical trial on its bivalent vaccine in China since September 2023. The results from Phase I/II clinical trial demonstrated that the vaccine candidate has favorable safety and immunogenicity.SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1, which has supplied the Chinese government's vaccination campaign and stockpiling program. Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sinovac-initiated-phase-iii-clinical-100400775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVA","BK4134","III","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVA\",params:#limit:5,,,undefined,":[{"date":"2025-07-10","symbol":"SVA","amount":55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1752154200000,"name":"科兴生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-09","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1752120000000,"payDate":"2025-07-09"},{"market":"US","date":"2022-04-29","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1651204800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-12-31","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1640926800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-09-17","symbol":"SVA","fiscalQuarterEnding":"2021/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1631851200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2021-06-29","symbol":"SVA","fiscalQuarterEnding":"2021/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1624939200000,"reportTimeType":"","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVA\",market:\"US\",,,undefined,":[{"executeDate":"2025-07-10","recordDate":"2025-05-23","paymentDate":"2025-07-09","value":55,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVA","date":"2021-09-21","current":5.82081,"percent":0.24257,"low":-100.201212,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"high":42.074882,"avg":0.136365,"sd":42.133061,"marketCap":642436987},"quantilePoints":[{"date":"2020-06-12","current":14.24256,"twenty":-59.560853,"median":25.202224,"eighty":133.776731,"marketCap":639903982},{"date":"2020-06-19","current":14.24256,"twenty":-59.560853,"median":25.078985,"eighty":133.776731,"marketCap":639903982},{"date":"2020-06-26","current":14.24256,"twenty":-59.560853,"median":24.986557,"eighty":133.776731,"marketCap":639903982},{"date":"2020-07-02","current":17.165727,"twenty":-59.560853,"median":24.940342,"eighty":133.776731,"marketCap":639903982},{"date":"2020-07-10","current":17.165727,"twenty":-59.560853,"median":24.863319,"eighty":133.776731,"marketCap":639903982},{"date":"2020-07-17","current":17.165727,"twenty":-59.560853,"median":24.709271,"eighty":133.776731,"marketCap":639903982},{"date":"2020-07-24","current":17.165727,"twenty":-59.560853,"median":24.647652,"eighty":133.776731,"marketCap":639903982},{"date":"2020-07-31","current":17.165727,"twenty":-59.560853,"median":24.616842,"eighty":133.776731,"marketCap":639903982},{"date":"2020-08-07","current":17.165727,"twenty":-59.560853,"median":24.555223,"eighty":133.776731,"marketCap":639903982},{"date":"2020-08-14","current":17.165727,"twenty":-59.560853,"median":24.431985,"eighty":132.906863,"marketCap":639903982},{"date":"2020-08-21","current":17.165727,"twenty":-59.560853,"median":24.370365,"eighty":42.074882,"marketCap":639903982},{"date":"2020-08-28","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":42.074882,"marketCap":639903982},{"date":"2020-09-04","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":42.074882,"marketCap":639903982},{"date":"2020-09-11","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":42.074882,"marketCap":639903982},{"date":"2020-09-18","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":42.074882,"marketCap":639903982},{"date":"2020-09-25","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":39.649553,"marketCap":639903982},{"date":"2020-10-02","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-10-09","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-10-16","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-10-23","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-10-30","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-11-06","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-11-13","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-11-20","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-11-27","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-04","current":29.948237,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-11","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-18","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-24","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-31","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2021-01-08","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-15","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-22","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-29","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-05","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-12","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-19","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-26","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-05","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-12","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-19","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-26","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-01","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-09","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-16","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-23","current":5.79786,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-30","current":5.82081,"twenty":-61.894113,"median":24.171596,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-07","current":5.82081,"twenty":-61.894113,"median":24.081398,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-14","current":5.82081,"twenty":-61.894113,"median":23.985687,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-21","current":5.82081,"twenty":-61.894113,"median":23.781276,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-28","current":5.82081,"twenty":-61.894113,"median":23.705864,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-04","current":5.82081,"twenty":-61.894113,"median":23.662388,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-11","current":5.82081,"twenty":-61.894113,"median":23.535556,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-18","current":5.82081,"twenty":-61.894113,"median":23.44385,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-25","current":5.82081,"twenty":-62.119913,"median":23.213593,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-02","current":5.82081,"twenty":-62.119913,"median":22.996932,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-16","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-23","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-30","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-06","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-13","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-20","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-27","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-03","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-10","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-17","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-24","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-01","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-08","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-15","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-22","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-29","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-05","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987}],"updateTime":1749452830685}}}